Amgen's Neulasta gains another biosimilar competitor as sales slip
Neulasta, one of Amgen’s oldest drug franchises, has another biosimilar to contend with.
German pharma Fresenius Kabi announced on Tuesday that the FDA has approved its pegfilgrastim biosimilar, to be marketed as Stimufend. The drug will add to a growing arsenal of biosimilars used to treat neutropenia, a condition common among chemotherapy patients where neutrophils, a type of white blood cell, are too low.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.